Special guest seminar

Johan Hartman, Karolinska Institute, Sweden
Precision pathology – from molecule to drug development

Dr Hartman is a principal investigator at Karolinska Institutet, Dept of Oncology and Pathology. His research focuses on breast cancer diagnosis with emphasis on tumor heterogeneity and ex vivo drug profiling. He has co-published several papers on the role of heterogeneity and cancer stem cells for therapeutic resistance. His team also has interest in image analysis for histopathology. Proliferation is a central factor for breast tumorigenesis but also for subclassification of tumors. Hartmans team has worked many years to develop computer-assisted methods to classify breast cancers based on proliferation. Currently they are applying deep-learning algorithms to improve cancer diagnosis. Dr Hartman is a clinically active breast pathologist at Karolinska University Laboratory and head of the Swedish expert group in breast pathology (KVAST-bröstcancer).

Some selected papers:
Kim C, et al. Chemoresistance Evolution in Triple-Negative Breast Cancer Delineated by Single-Cell Sequencing. Cell. 2018 May 3

Ullah I, et al. Evolutionary history of metastatic breast cancer reveals minimal seeding from axillary lymph-nodes. J Clin Invest. 2018 Apr 2

Ma R, et al. Estrogen receptor β as a therapeutic target in breast cancer stem cells. J Natl Cancer Inst. 2017 Mar 1

Rantalainen M, et al. Sci Rep. 2016 Nov 30.

Stålhammar G, et al. Digital image analysis outperforms manual biomarker assessment in breast cancer. Mod Pathol. 2016 Apr 29